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Abstract 26 
Bacterial infections remain the leading killer worldwide which is worsened by the continuous 27 
emergence of antibiotic resistance. In particular, antibiotic-resistant Enterobacteriaceae is 28 
prevalent and extremely difficult to treat. Reusing existing drugs and rejuvenating the 29 
therapeutic potential of existing antibiotics represent an attractive novel strategy. 30 
Azidothymidine (AZT) is an antiretroviral drug which is used in combination with other 31 
antivirals to prevent and to treat HIV/AIDS. AZT is also active against Gram-negative 32 
bacteria but has not been developed for that purpose. Here we investigated in vitro and in 33 
vivo efficacy of AZT  in combination with colistin against antibiotic-resistant 34 
Enterobacteriaceae including extended-spectrum beta-lactamase (ESBL), New Delhi 35 
metallo-beta-lactamase 1 (NDM) or the mobilized colistin resistance (mcr-1) producing 36 
strains. Minimum inhibitory concentration was determined using the broth microdilution 37 
method. The combinatory effect of AZT and colistin was examined using the checkerboard 38 
method and time-kill analysis. A murine peritoneal infection model was used to test the 39 
therapeutic effect of the combination of AZT and colistin. Fractional inhibitory concentration 40 
index from checkerboard assay demonstrated that AZT synergized with colistin against 41 
61% and 87% of ESBL-producing Escherichia coli and Klebsiella pneumoniae, respectively, 42 
100% of NDM-1-producing strains and 92% of mcr-1 producing E. coli. Time-kill analysis 43 
demonstrated significant synergistic activities when AZT was combined with colistin. In the 44 
murine peritoneal infection model, AZT in combination with colistin showed augmented 45 
activities of both drugs in the treatment of NDM-1 K. pneumoniae and mcr-1 E. coli 46 
infections. AZT and colistin combination poses a potential to be used coherently to treat 47 
antibiotic-resistant Enterobacteriaceae infections. 48 
Keywords: Enterobacteriaceae, azidothymidine, colistin, ESBL, NDM-1, mcr-1  49 
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INTRODUCTION 51 
Bacterial infection remains a leading killer worldwide (1) and antibiotic resistance continues 52 
to plague the effective control of this pandemic health problem (2, 3). In particular, there is 53 
an urgent global threat with an increasing prevalence of multidrug-resistant 54 
Enterobacteriaceae, especially carbapenem-resistant Enterobacteriaceae (CRE) such as 55 
New Delhi Metallo-beta-lactamase-1 (NMD) carriers (4-8) which are extremely resistant to 56 
almost all of our antibiotics (3, 9). As a result, our ability to treat serious community and 57 
nosocomial acquired infections is rapidly diminishing (10). Unfortunately, the number of new 58 
antibiotics reaching the market annually is unable to keep up with the development of 59 
bacterial antibiotic resistance (11-14). The drug discovery process itself is arduous and 60 
costly and it is almost impossible to produce a large group of effective antibiotics within a 61 
short period of time to combat antibiotic resistance. Therefore, a different therapeutic 62 
approach is needed to replenish our antibiotic reservoir against resistant bacteria and the 63 
most promising of such strategies is to reuse existing drugs and to restore the therapeutic 64 
potencies of existing antibiotics (15, 16).  65 
Azidothymidine (3’-azido-3’-deoxythymidine AZT) is an antiretroviral drug which is used in 66 
combination with other antivirals to prevent and to treat HIV/AIDS. It inhibits viral reverse 67 
transcriptase and was the first effective treatment for HIV/AIDS (17) entering the US market 68 
in 1986. AZT is also active against Gram-negative bacteria (18-22) but has not been 69 
developed or approved for that purpose. It is thought to inhibit bacterial DNA replication by 70 
chain termination. Resistance to AZT occurs in bacteria and has been attributed to two 71 
mechanisms, one of which is unknown and the other is a deficiency of thymidine kinase 72 
which phosphorylates inactive AZT into the active triphosphate form (23).  73 
The rapid emergence of CRE which are often resistant to many other antibiotics, has left 74 
the world with colistin as the last resort treatment option. The use of colistin has led to high 75 
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rates of colistin resistance in patients with infections due to K. pneumoniae 76 
carbapenemases (KPC) - producing strains (24). A recent study also found that 77 
approximately 10% of NDM-1 producing CRE were colistin resistant in the UK (25)  and 78 
plasmid-born colistin resistance was also found recently in animals and humans (26). 79 
Hence it is crucial to boost the effectiveness of colistin against colistin resistant bacteria. 80 
However, treatment with colistin has been associated with both nephron- and neurotoxic 81 
adverse effects (27). It is not known if AZT can synergistically act with colistin to treat 82 
multidrug-resistant Enterobacteriaceae infections which allows the administration of both 83 
drugs at lower doses to achieve a desired therapeutic effect while minimising the side 84 
effects and to prevent emergence of antibiotic resistance (15, 28).  85 
In this study, we performed the first study to retrospectively test the in vitro activities of AZT 86 
in combination with colistin against 74 antibiotic-resistant Enterobacteriaceae including 87 
NDM-1, mcr-1 and ESBL producing strains. In addition, the therapeutic effectiveness of 88 
AZT plus colistin was tested using a mouse peritoneal infection model. 89 
MATERIALS AND METHODS 90 
Bacterial strains and growth conditions. The bacterial strains used were 74 antibiotic-91 
resistant Enterobacteriaceae strains including 7 strains harboring the blaNDM plasmid which 92 
were ATCC BAA-2468 (Enterobacter cloacae), ATCC BAA-2469 (E. coli), ATCC BAA-2470 93 
(K. pneumoniae), ATCC BAA-2471 (E. coli), ATCC BAA-2472 (K. pneumoniae) and ATCC 94 
BAA-2473 (K. pneumoniae) and NCTC13443 (K. pneumoniae), 13 colistin resistant E. coli 95 
containing mcr-1 plasmid (Table S1) (29-32), 54 antibiotic-resistant Gram-negative strains 96 
(23 E. coli and 31 K. pneumoniae) isolated in the hospitals in Hong Kong, Taiwan, Thailand, 97 
Korea, India, Singapore, Malaysia, Philippines and St George’s Hospital, London. The 98 
bacterial isolates were grown in nutrient broth (Oxoid, UK), on tryptone soya agar plates 99 
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(Fluka, UK) or on Chrome agar Orientation plates (BD, UK). AZT was obtained from Sigma-100 
Aldrich, UK as powder form.   101 
Susceptibility tests of antibiotics and AZT. The minimum inhibitory concentrations (MIC) 102 
of antibiotics and AZT were determined using the broth microdilution method in accordance 103 
with the Clinical and Laboratory Standards Institute (CLSI) guidelines (33). MIC was 104 
performed using 96-well polystyrene micro-titre plates (Fisher Scientific, UK). The 105 
antibiotics were diluted with two-fold serial dilutions in triplicate followed by addition of a 106 
standard bacterial suspension of 1-5 × 105 CFU/mL in cation adjusted Mueller Hinton Broth 107 
(CA-MHB, Sigma-Aldrich, UK).  After 16 - 20 hours of incubation at 37°C, the optical density 108 
(OD) readings were determined using an absorbance microplate reader (ELx800, BioTek). 109 
The lowest concentration of an antibiotic which produced a similar OD reading as the 110 
control (medium only) was determined as MIC value. The MIC for each agent was identified 111 
as the lowest concentration required to inhibit bacterial growth. The MIC50 and MIC90 values 112 
were calculated to investigate the lowest concentrations required to inhibit growth in 50% 113 
and 90% of the strains, respectively.  114 
Detection of ESBLs in the antibiotic-resistant Gram-negative isolates. Detection of the 115 
multidrug-resistant Enterobacteriaceae producing extended spectrum β-lactamases were 116 
performed according to the UK standard for microbiology investigations (34) using 117 
CHROMID ESBL (bioMérieux, UK) (35), double-disc synergy test (DDST) (36) and 118 
combination disc test (CDT) (34). Detection of ESBL genes were performed by polymerase 119 
chain reaction (PCR) using the primers (Table S2) followed by DNA sequencing of the PCR 120 
fragments (DNA Sequencing & Services, University of Dundee). 121 
Checkerboard assays to determine combination effects of AZT with antibiotics. 122 
Combination of AZT and antibiotic was prepared using 96 well polystyrene micro-titre plates 123 
with drug concentrations starting two-fold higher than their MIC values, and were then 124 
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serially diluted in a two-fold manner. The two drugs were mixed in a 96 well plate followed 125 
by addition of a standard bacterial suspension at 1-5 x 105 CFU/mL in CA-MHB. After 126 
incubation for 16 - 20 hours at 37°C, the OD values were read using the ELx800 127 
absorbance microplate reader (BioTek). The combinatory effects were determined by 128 
calculating the fractional inhibitory concentration index (FICI) of the combination as follows: 129 
(MIC of Drug A, tested in combination) / (MIC of Drug A, tested alone) + (MIC of Drug B, 130 
tested in combination) / (MIC of Drug B, tested alone). Synergy was defined as a FICI ≤0.5, 131 
no interaction was identified with an FICI >0.5 but <4 and antagonism if the FICI was >4 132 
(37).  133 
Time-Kill analysis of antibiotics alone and in combination with AZT against log-phase 134 
bacteria. A range of different concentrations of colistin and AZT was chosen according to 135 
the checkerboard evaluation as a synergistic combination.  The drugs was prepared in a 136 
two-fold serial dilution and was added in combination or alone to log phase bacterial 137 
cultures suspension containing 1 x 107 CFU/mL (38) in CA-MHB, and incubated at 37°C.  138 
Viability expressed as log CFU/mL was determined at 0, 2, 4, 8, 24 and 48 hours of 139 
incubation by plating out 100 µL of serial dilutions of the cultures onto tryptone soy agar 140 
(Oxoid) plates. The colonies on the agar plates were counted using an aCOLyte colony 141 
counter (Synbiosis) and analysed with the counter’s software. Synergistic activity was 142 
confirmed as a≥2-log10 decrease in CFU counts at 24 hours of the combination compared 143 
to the antibiotic alone, in addition to a ≥2-log10 decrease compared to the zero hour count 144 
(39).  145 
Mouse peritoneal infection model. Female ICR mice (five to six weeks old, body weight 146 
24 - 26 g) were used (Harlan UK Ltd) for the mouse peritoneal infection model (40). Human 147 
medicines of AZT (Retrovir® 10 mg/ml, ViiV Healthcare UK Ltd) and colistin 148 
methanesulfonate (CMS) (Colomycin® injection, Forrest) were used in the mouse study. 149 
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Mice were infected intraperitoneally with two hundred microliter bacterial suspension 150 
containing 107 CFU of the NDM-1 K. pneumoniae BAA2472 and the mcr-1 E. coli strain 151 
Af40 (Table S1).  After 30 minutes of infection, AZT (2, 5 or 10 mg/kg) and CMS (10, 20 or 152 
30 mg/kg) singly or in combination was injected intravenously into the mice.  A group of 153 
mice was treated with saline as a control group. At 30 minutes after infection (treatment 154 
starting), 2 and 6 hours after treatment, 4 mice in each group were sacrificed and 1 ml 155 
sterile PBS was injected intraperitoneally followed by gently massaging of the abdomen.  156 
Peritoneal fluid was sampled aseptically. The fluid was diluted in a serial of 10-fold dilutions 157 
and 100 µl of each dilution were plated onto tryptone soy agar (Oxoid) plates. Viability was 158 
defined as Log CFU/ml of peritoneal fluid.  159 
The animal husbandry guidelines and all animal experiments were performed according to 160 
the Animals Scientific Procedures Act, 1986 (an Act of the Parliament of the United 161 
Kingdom 1986 c. 14) (Home Office Project licence Number 70/7077) with approval from St 162 
George’s, University of London ethics committee.  163 
Statistical analysis. The significance of differences between experimental groups was 164 
determined by Student’s t test. P values <0.05 were considered significant. 165 
RESULTS 166 
In vitro susceptibility of AZT and colistin against 74 antibiotic-resistant 167 
Enterobacteriaceae. The MICs for aztreonam, amoxicillin, piperacillin, cefotaxime, 168 
ceftriaxone, ceftazidime, meropenem, amikacin, gentamicin, tobramycin, ciprofloxacin, 169 
levofloxacin, trimethoprim, nitrofurantoin, rifampicin, tigecycline, colistin, polymyxin B, and 170 
AZT were determined against the 7 NDM-1 strains. As seen in Table 1, compared with the 171 
antibiotic breakpoints (41) resistance was found in all strains for nearly all antibiotics. Only 172 
certain strains were susceptible to a number of antibiotics such as nitrofurantoin (BAA-173 
2469), amikacin (BAA-2471) and tigecycline (BAA-2469, BAA-2470 and BAA-2471). 174 
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However, all NDM-1 strains were susceptible to colistin (41). AZT MIC ranged from 2 to 4 175 
mg/L. 176 
The MICs for the antibiotics and AZT were also determined against the 54 antibiotic-177 
resistant isolates, E. coli and K. pneumoniae. As shown in Table 2 and Table S3, these 178 
strains were resistant to monobactam, penicillins and cephalosporins but were susceptible 179 
to carbapenems. Resistance was seen for gentamicin, ciprofloxacin and trimethoprim. 90% 180 
of the strains were susceptible to tigecycline and colistin. The MIC for AZT ranged from 181 
0.25 to 64 for E. coli and 2 to 32 for K. pneumoniae. The 54 multidrug-resistant E. coli and 182 
K. pneumoniae were tested for ESBL production using commercial ESBL-testing systems 183 
and demonstrated that these were ESBL producing strains (Table S3). 184 
For colistin resistant strains, the MIC for AZT ranged from 8 to 64 with MIC50 at 8 mg/L and 185 
MIC90 at 64 mg/L. The range of MIC for colistin was 2 to 8 mg/L with MIC50 at 4 mg/L and 186 
MIC90 at 8 mg/L.  187 
Checkerboard analysis of combination effects. The effects of combining AZT with 188 
colistin were determined using checkerboard assays against all the 74 strains. As shown in 189 
Table 3, the combination of AZT with colistin showed synergistic activity with FIC index ≤0.5 190 
against 60.87% of the ESBL E. coli, 87.1% of the ESBL K. pneumoniae, 100% of NDM-1 191 
strains and 92.31% of colistin resistant (mcr-1) E. coli. With the concentration of AZT range 192 
from 0.25 to 16 mg/L, the MICs of colistin were significantly reduced from 32 to 256-fold 193 
against the seven NDM-1 strains, 2 to 64-fold against ESBL E. coli, 2 to 512 fold against 194 
ESBL K. pneumoniae and 4 to 256 fold against mcr-1 containing E. coli.  195 
Time kill analysis of AZT in combination with colistin against log-phase bacteria. The 196 
synergistic combination of AZT and colistin was performed using time kill assays against  7 197 
NDM-1,  3 ESBL E. coli and 3 ESBL  K. pneumoniae and  3 mcr-1 E. coli  which showed an 198 
FICI <0.5 for the combination. The characteristics of the 16 strains are shown in Table S4. 199 
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A range of different concentrations was used starting from 2 fold or MIC level for each of 200 
the two drugs. Data from representative strains are shown to display combinations with the 201 
synergistic activities. As shown in Figure 1 for the NDM-1 K. pneumoniae BAA2472, colistin 202 
at 2 mg/L was bactericidal until 7 hours followed by a regrowth and at 1 mg/L (MIC) 203 
inhibited bacterial growth.  AZT at 4, 2 (MIC) and 1 mg/L was bactericidal showing dose-204 
dependent kill and regrowth occurred after 8 hours of drug exposure. However when 205 
colistin at 2 mg/L combined with 4 and 2 mg/L of AZT, significant killing to the limit of 206 
detection of initial bacterial counts was achieved within 4 hours, and the same kill was seen 207 
at 8 hours when the same concentration of colistin combined with 1 mg/L of AZT (Figure 208 
1A-1C). When colistin at 1 mg/L was combined with 4, 2 and 1 mg/L of AZT, kill at the level 209 
of limit of detection was achieved at 8 hours (Figure 1E-1F). No bacterial regrowth was 210 
observed in both 24 (Figure 1) and 48 hours of post-treatment (data not shown).  211 
As shown in Figure 2, for the mcr-1 E. coli strain Af40 (Table S1), colistin at 8 mg/L (MIC) 212 
inhibited bacterial growth and at 4 mg/L showed the similar growth pattern as the control. 213 
AZT at 4, 2 and 1 mg/L reduced the initial counts till 4 hours and regrowth was seen.  When 214 
colistin at 8 mg/L was combined with the concentrations of 4, 2 and 1 mg/L AZT, kill to the 215 
limit of detection was seen at 8 hours (Figure 2A – 2C). The same effects were seen when 216 
colistin at 4 mg/L was combined with 4 mg/L of AZT (Figure 2D).  Reduced effects were 217 
seen when colistin at 4 mg/L with 4 and 2 mg/L of AZT and kill to the limit of detection was 218 
shown at 24 hours (Figure 2E and 2F). 219 
Significant synergistic activity was also observed in other 6 NDM-1 strains (Figure S1-S6), 3 220 
ESBL E. coli (Figure S7-S9) and 3 ESBL K. pneumoniae (Figure S10-S12) and two colistin 221 
resistant mcr-1 E. coli (Figure S13-S14). 222 
In vivo combination activities of AZT combined with colistin. The in vivo activity of AZT 223 
combination with colistin was studied using a murine peritoneal infection model.  A dose 224 
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range study of the two drugs was performed.  For AZT, the minimal dosages (5 mg/kg) was 225 
chosen which only inhibited bacterial growth but provide significant enhanced activities 226 
when combined with CMS. For CMS, we found that 10 to 30 mg/kg showed no activities 227 
against the infected bacteria. Therefore, for the colistin sensitive NDM-1 strain, we used 10 228 
mg/kg of CMS and for the mcr-1 E. coli, we used 20 mg/kg of CMS. The drugs were tested 229 
singly or in combination against the NDM-1 K. pneumoniae BAA2472 and the mcr-1 E. coli 230 
strain Af40 (Table S4).   231 
As shown in Figure 3A, for strain K. pneumoniae BAA2472, compared with the untreated 232 
control, colistin at 10 mg/kg showed no activities at both 2 and 6 hours and AZT at 5 mg/kg 233 
inhibited bacterial growth. Combination of colistin with AZT, although only showing inhibition 234 
at 2 hours, exhibited 2.72 log kill of the bacterium at 6 hours.  The difference of the bacterial 235 
numbers between zero hour and 6 hours was significant (P <0.001, n=4).  For E. coli strain 236 
Af40 (Figure 3B), colistin at 20 mg/kg showed the same growth pattern as the control and 237 
AZT inhibited bacterial growth.  Combination of colistin with AZT exhibited 1.32 and 2.96 238 
log kill of the bacterium at 2 and 6 hours, respectively.  The difference of the bacterial 239 
numbers between zero hour and 2 hours or 6 hours was significant (P <0.01 and 0.001, 240 
respectively, n=4). In both untreated control groups and the colistin treated group, all 241 
animals developed mild clinical signs such as transiently hunched posture at 6 hours after 242 
infection. The animals in other treatment groups showed no discomfort with normal and 243 
heathy behaviors. All animals were sacrificed at 6 hours after treatment according to the 244 
restriction of adverse effects in the project licence. 245 
 246 
DISCUSSION 247 
In this study, we demonstrated for the first time that AZT synergized with colistin against 74 248 
antibiotic-resistant Enterobacteriaceae including NDM-1, ESBL and colistin resistant 249 
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strains.  The antibiotic-resistant Enterobacteriaceae isolates used in the study covered a 250 
broad geographic distribution. The colistin resistant strains were from some European 251 
countries and South Africa (29-31). The 7 NDM-1 strains represented the most resistant 252 
type of Enterobacteriaceae.   253 
The clinical efficacy of AZT has been demonstrated to reduce morbidity and mortality in 254 
patients with asymptomatic or acute human immunodeficiency virus (HIV) disease (43, 44). 255 
In patients, the oral dosage is 250 – 300 mg twice daily and intravenous infusion is 0.8 – 1 256 
mg/kg every 4 hours for up to 2 weeks.  It has been shown that 120 mg iv dosing produced 257 
an AUC of 0.0014 mg.h/L and a Cmax of 0.0015 mg/L while 200 mg oral dosing gave rise 258 
to an AUC of 0.0017 mg.h/L and a Cmax of 0.0018 mg/L (45). AZT has been shown to be 259 
active against Gram-negative bacteria (18-20), it is not known if the concentrations used 260 
clinically are sufficient to treat bacterial infections in humans. 261 
Colistin is effective against multidrug-resistant but colistin susceptible Pseudomonas 262 
aeruginosa, K. pneumoniae, Acinetobacter (46) and importantly NDM-1 carrying 263 
Enterobacteriaceae (8). There is increasing evidence to show that colistin resistance is on 264 
the rise, especially the discovery of plasmid born colistin resistance worldwide (26, 47, 48).    265 
It is critically important to preserve and prolong the life of the last resort of antibiotic by 266 
enhanced combination therapy.  Here we have shown that in combination with AZT, colistin 267 
MIC was significantly reduced, especially against mcr-1 containing colistin resistant strains.  268 
The enhanced activity of colistin in combination with AZT was confirmed with time kill 269 
assays which provided dynamic measures of bactericidal activities of the combination over 270 
time. In colistin mono exposure, complete eradication of the NDM-1 K. pneumoniae 271 
BAA2472 or mcr-1 E. coli Af40 strains required much higher concentrations of the drug 272 
(data not shown), however, more than 4 to 16-fold lower concentrations of colistin when 273 
combined with AZT achieved the same effect.  This is significant as enhancement of colistin 274 
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combination with AZT will likely reduce the dose of colistin but retain maximal therapeutic 275 
efficacy hence minimize its toxic profile.  These data suggest that further clinical 276 
development of a colistin plus AZT combination may be able to achieve an effective lower 277 
dose colistin therapy against colistin-sensitive and colistin-resistant infections. 278 
Bacterial infections caused by carbapenem resistant strains are life threatening and 279 
effective treatment is difficult to achieve. The last resort treatment option is to use colistin 280 
(9, 49). Previous studies have shown that in bacteria AZT needs to be converted to the 281 
nucleotide to inhibit bacterial DNA replication (50) and that bacterial thymidine kinase is 282 
responsible for the initiation of the activation process - phosphorylation of AZT (23, 50). 283 
Other antibiotics such as ciprofloxacin also inhibit DNA replication by blocking GyrA. But 284 
comparison of the resistance profiles of ciprofloxacin and AZT are very different (see Table 285 
3). This suggests that AZT has a different mechanism of action to other antibacterial agents 286 
which are in the market. Rather, AZT is likely to act on a new target in bacteria. Further 287 
studies on how AZT acts against Gram-negative bacteria are underway in our laboratories 288 
by analysis of AZT mutants with next-generation sequencing and investigation of the AZT 289 
effect on bacteria by performing Bacterial Cytological Profiling (BCP).  290 
The therapeutic effectiveness of AZT and colistin combinations was also examined using a 291 
mouse peritoneal infection model. As a potential therapeutic agent, AZT has been used to 292 
treat HIV. Its bactericidal activity has been reported in vivo (19).   Here we demonstrate that 293 
AZT at 5 mg/kg inhibited the NDM-1 K. pneumoniae BAA2472 and the mcr-1 E. coli strain 294 
Af40 growth in the mouse peritoneal infection. However, the combination of AZT with 295 
colistin improved the therapeutic activities of each single agent with significant kill of the 296 
bacteria at 2 or 6 hours in mouse peritoneal cavity. Most importantly, when colistin 297 
methanesulfonate was completely ineffective up to 6 hours of treatment, the addition of 298 
AZT was able to significantly reduce bacterial counts and attenuate the clinical signs in the 299 
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animals. Here we used colistin methanesulfonate instead of colistin sulfate. The reason 300 
was that colistin methanesulfonate is used clinically and is less toxic than colistin sulfate in 301 
mice (51). Colistin methanesulfonate is a prodrug which needs to convert to the active form 302 
of colistin (52). The conversion normally delays the activity of the drug (52).  Here we 303 
demonstrated that with the addition of AZT, the effect of colistin methanesulfonate and AZT 304 
was significantly increased. Collectively, the data show that the application of AZT and 305 
CMS combination therapy in vivo offers the potential to increase both colistin and AZT 306 
activities against antibiotic-resistant Enterobacteriaceae. 307 
In conclusion, in this proof-of-principle study, we demonstrated the high therapeutic efficacy 308 
of AZT-plus-colistin combination therapy against antibiotic-resistant Enterobacteriaceae, 309 
including mcr-1, NDM-1 and ESBL strains. ESBL strains were confirmed using 310 
commercially-accepted phenotypical methods currently using in clinical practice. The 311 
interaction between the genotypic characteristics of ESBL strains and this novel 312 
combination therapy deserves further investigation.  Importantly, we showed that the 313 
combination of AZT with colistin significantly reduced the bacterial burden in vivo. This 314 
early groundwork lays the foundation for further validation in clinical trials enabling 315 
translation of the combination therapy into clinical benefits for patients. 316 
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Figure legends  499 
Figure 1. Time Kill analysis showing the effects of AZT in combination with colistin against 500 
NDM-1 K. pneumoniae BAA2472. AZT and colistin alone or in combination were added to 501 
the log phase cultures and CFU counts were carried out at different time points. 502 
Combination concentrations of AZT and colistin are colistin 2 mg/L + AZT 4 mg/L  (A), 503 
colistin 2 mg/L + AZT 2 mg/L  (B), colistin 2 mg/L + AZT 1 mg/L  (C), colistin 1 mg/L + AZT 504 
4 mg/L  (D), colistin 1 mg/L + AZT 2 mg/L  (E) and colistin 1 mg/L + AZT 1 mg/L  (F). The 505 
dash line is the limit of detection in the assay (30 CFU/ml). 506 
Figure 2. Time Kill analysis showing the effects of AZT in combination with colistin against 507 
mcr-1 colistin resistant E. coli Af40. AZT and colistin alone or in combination were added to 508 
the log phase cultures and CFU counts were carried out at different time points. 509 
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Combination concentrations of AZT and colistin are colistin 8 mg/L + AZT 4 mg/L (A), 510 
colistin 8 mg/L + AZT 2 mg/L (B), colistin 8 mg/L + AZT 1 mg/L (C), colistin 4 mg/L + AZT 4 511 
mg/L (D), colistin 4 mg/L + AZT 2 mg/L (E) and colistin 4 mg/L + AZT 1 mg/L (F). The dash 512 
line is the limit of detection in the assay (20 CFU/ml). 513 
Figure 3. Effects of AZT in combination with colistin against the NDM-1 K. pneumoniae 514 
BAA2472 and the mrc-1 E. coli strain Af40 in a mouse peritoneal infection model. A. Mice 515 
were infected with strain BAA2472. Treatment was initiated 30 minutes after infection with 516 
AZT (5 mg/kg), CMS (10 mg/kg) and AZT plus CMS.  B. Mice were infected with strain 517 
Af40. Treatment was initiated 30 minutes after infection with AZT (5 mg/kg), CMS (20 518 
mg/kg) and AZT plus CMS.  Bacterial counts in the peritoneal cavity were determined from 519 
4 mice for each group at 0 hour before and 2 and 6 hours post-treatment. The data has 520 
been repeated once. ** indicates p≤0.01. *** indicates p≤0.001.  521 
 522 
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Table 1. MIC values of antibiotics and AZT against 7 NDM-1 producing strains 
 
    
MIC (mg/L) 
 
  
Antibiotics 
NCTC13443 
K. pneumoniae 
BAA – 2468 
E. cloacae 
BAA – 2469 
E. coli 
BAA – 2470 
K. pneumoniae 
BAA – 2471 
E. coli 
BAA – 2472 
K. pneumoniae 
BAA – 2473 
K. pneumoniae 
Cefotaxime >2048 512 512 >2048 >2048 >2048 2048 
Ceftazidime >2048 512 >2048 >2048 >2048 >2048 512 
Ceftriaxone >4096 4096 2048 >4096 >4096 >4096 >4096 
Aztreonam >2048 1024 32 512 >2048 2048 1024 
Piperacillin >2048 256 1024 1024 >2048 >2048 1024 
Meropenem 128 64 32 128 128 128 16 
Gentamicin >256 >256 >256 >256 >256 >256 >256 
Amikacin 8 >256 >256 >256 16 >256 8 
Tobramycin 32 >1024 1024 128 16 >1024 16 
Ciprofloxacin >64 64 64 8 64 32 >64 
Levofloxacin 32 32 16 4 16 32 32 
Trimethoprim >256 >256 >256 >256 >256 >256 >256 
Nitrofuratoin 256 >256 32 >256 64 256 256 
Tigecycline 1 4 0.5 1 0.5 4 1 
Rifampicin 1024 16 4 256 16 1024 1024 
Colistin 0.25 0.5 0.125 0.5 0.125 1 0.25 
AZT 4 2 2 2 4 2 2 
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Table 2. MIC values of antibiotics and AZT against ESBL and mcr-1 producing E. coli and K. pneumoniae  
 
-, not tested 
 
 
 
 E. coli (23) K. pneumoniae (31) mcr-1 E. coli (13) 
 
MIC range 
(mg/L) MIC50 MIC90 MIC range (mg/L) MIC50 MIC90 
MIC range 
(mg/L) MIC50 MIC90 
Aztreonam 1 - 256 128 256 32 - 1024 128 256 - - - 
Amoxicillin 128 - 2048 256 2048 256 - 1024 512 1024 - - - 
Piperacillin 1 - 512 16 256 16 - 1024 512 1024 - - - 
Cefotaxime 64 - 2048 512 1024 32 - 1024 512 1024 - - - 
Ceftazidime 8 - 512 256 512 32 - 1024 128 1024 - - - 
Ceftriaxone 128 - 1024 512 1024 64 - 1024 256 512 - - - 
Gentamicin 0.5 - 256 128 128 16 - 128 128 128 - - - 
Meropenem 0.03 - 0.25 0.125 0.25 0.03 - 2 0.03 1 - - - 
Imipenem 0.03 – 0.25 0.125 0.25 0.06 - 128 0.25 2 - - - 
Ciprofloxacin 0.03 - 256 64 256 0.06 - 256 128 128 - - - 
Trimethoprim 0.06 - 128 64 128 0.125 - 128 64 128 - - - 
Tigecycline 0.125 - 4 0.5 0.5 0.5 -8 1 4 - - - 
Colistin 0.5 - 4 0.5 1 0.5 - 2 0.5 1 2 - 8 4 8 
AZT 0.25 - 64 4 32 2 - 32 8 32 8 - 64 8 64 
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Table 3. Combination activities of AZT with colistin 
 
  
Total numbers (%) of strains 
Strains Combination activity FICI AZT + colistin 
ESBL E. coli synergy ≤ 0.5 14 (60.87%) 
 
no interaction 0.56 -1 9 (39.13%) 
 
antagonism >4 0 
ESBL K.  pneumoniae synergy ≤ 0.5 27 (87.10%) 
 
no interaction 0.56 -1 4 (12.90%) 
 
antagonism >4 0 
NDM-1 Strains synergy ≤ 0.5 7 (100%) 
 
no interaction 0.56 -1 0 
 
antagonism >4 0 
mcr-1 E. coli synergy ≤ 0.5 12 (92.31%) 
 
no interaction 0.56 -1 1 (7.69%) 
 
antagonism >4 0 
 
 o
n
 N
ovem
ber 1, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
01
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
F
U
/m
L
Time (hours)
Control
Colisi�n 2 mg/L
AZT 4 mg/L
Colis�n + AZT
A
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
F
U
/
m
l
Time (hours)
Control
Colisi�n 2 mg/L
AZT 2 mg/L
Colis�n + AZT
B
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
F
U
/m
L
Time (hours)
Control
Colisi�n 2 mg/L
AZT 1 mg/L
Colis�n + AZT
C
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
F
U
/m
L
Time (hours)
Control
Colisi�n 1 mg/L
AZT 4 mg/L
Colis�n + AZT
D
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
F
U
/m
L
Time (hours)
Control
Colisi�n 1 mg/L
AZT 1 mg/L
Colis�n + AZT
F
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
F
U
/m
L
Time (hours)
Control
Colisi�n 1 mg/L
AZT 2 mg/L
Colis�n + AZT
E
 o
n
 N
ovem
ber 1, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
01
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
FU
/m
L
Time (hours)
Control
Colis�n 4 mg/L
AZT 1 mg/L
Colis�n + AZT
F
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
F
U
/m
L
Time (hours)
Control
Colis�n 8 mg/L
AZT 4 mg/L
Colis�n + AZT
A
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
F
U
/m
L
Time (hours)
Control
Colis�n 8 mg/L
AZT 1 mg/L
Colis�n + AZT
C
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
F
U
/m
L
Time (hours)
Control
Colis�n 8 mg/L
AZT 2 mg/L
Colis�n + AZT
B
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g
 C
F
U
/m
L
Time (hours)
Control
Colis�n 4 mg/L
AZT 2 mg/L
Colis�n + AZT
E
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Lo
g 
C
FU
/m
L
Time (hours)
Control
Colis�n 4 mg/L
AZT 4 mg/L
Colis�n + AZT
D
 o
n
 N
ovem
ber 1, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
01
2
3
4
5
6
7
8
9
10
Lo
g 
C
FU
/m
l
0 hour 2 hour 6 hour
***
A
0
1
2
3
4
5
6
7
8
9
10
Lo
g 
C
FU
/m
l
0 hour 2 hour 6 hourB
***
**
 o
n
 N
ovem
ber 1, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
